Varela Nelson M, Quiñones Luis A, Orellana Myriam, Poniachik Jaime, Csendes Attila, Smok Gladys, Rodrigo Ramón, Cáceres Dante D, Videla Luis A
Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Biol Res. 2008;41(1):81-92. Epub 2008 Aug 21.
CYP2E1 enzyme is related to nonalcoholic steatohepatitis (NASH) due to its ability for reactive oxygen species production, which can be influenced by polymorphisms in the gene. The aim of this study was to investigate hepatic levels, activity, and polymorphisms of the CYP2E1 gene to correlate it with clinical and histological features in 48 female obese NASH patients. Subjects were divided into three groups: (i) normal; (ii) steatosis; and (iii) steatohepatitis. CYP2E1 protein level was assayed in microsomes from liver biopsies, and in vivo chlorzoxazone hydroxylation was determined by HPLC. Genomic DNA was isolated for genotype analysis through PCR. The results showed that liver CYP2E1 content was significantly higher in the steatohepatitis (45%; p=0.024) and steatosis (22%; p=0.032) group compared with normal group. Chlorzoxazone hydroxylase activity showed significant enhancement in the steatohepatitis group (15%, p=0.027) compared with the normal group. c2 rare allele of RsallPstl polymorphisms but no C allele of Dral polymorphism was positively associated with CHZ hydroxylation, which in turn is correlated with liver CYP2E1 content (r=0.59; p=0.026). In conclusion, c2 allele is positively associated with liver injury in NASH. This allele may determine a higher transcriptional activity of the gene, with consequent enhancement in pro-oxidant activity of CYP2E1 thus affording liver toxicity.
细胞色素P450 2E1(CYP2E1)酶因其产生活性氧的能力而与非酒精性脂肪性肝炎(NASH)相关,该能力可受该基因多态性的影响。本研究的目的是调查48例肥胖女性NASH患者中CYP2E1基因的肝脏水平、活性和多态性,并将其与临床和组织学特征相关联。受试者分为三组:(i)正常组;(ii)脂肪变性组;(iii)脂肪性肝炎组。通过肝脏活检的微粒体检测CYP2E1蛋白水平,并通过高效液相色谱法测定体内氯唑沙宗羟基化情况。通过聚合酶链反应(PCR)分离基因组DNA进行基因型分析。结果显示,与正常组相比,脂肪性肝炎组(45%;p=0.024)和脂肪变性组(22%;p=0.032)的肝脏CYP2E1含量显著更高。与正常组相比,氯唑沙宗羟化酶活性在脂肪性肝炎组显著增强(15%,p=0.027)。RsallPstl多态性的c2罕见等位基因而非Dral多态性的C等位基因与氯唑沙宗羟基化呈正相关,而氯唑沙宗羟基化又与肝脏CYP2E1含量相关(r=0.59;p=0.026)。总之,c2等位基因与NASH中的肝损伤呈正相关。该等位基因可能决定该基因更高的转录活性,从而导致CYP2E1的促氧化活性增强,进而产生肝脏毒性。